Xenpozyme
Payments companies reported to CMS as associated with Xenpozyme. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Xenpozyme, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Xenpozyme
These are the largest totals companies reported as associated with Xenpozyme. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Joshua Baker | Chicago, IL | Clinical Genetics (M.D.) | $84,431.22 |
| Kyrieckos Aleck | Albuquerque, NM | Clinical Genetics (M.D.) | $44,679.09 |
| Jose Camacho | San Francisco, CA | Clinical Genetics (M.D.) | $38,933.74 |
| Melissa Wasserstein | New York, NY | Clinical Biochemical Genetics | $28,115.79 |
| Angelika Erwin | Cleveland, OH | Clinical Genetics (M.D.) | $22,578.07 |
| David Kronn | Valhalla, NY | Clinical Genetics (M.D.) | $17,659.70 |
| Carlos Prada | Chicago, IL | Clinical Genetics (M.D.) | $13,831.71 |
| Helio Pedro | Newark, NJ | Internal Medicine | $9,539.79 |
| Imre Noth | Charlottesville, VA | Pulmonary Disease | $5,999.50 |
| Kathryn Weaver | Cincinnati, OH | Clinical Genetics (M.D.) | $5,935.64 |
Prescribed Xenpozyme?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.